TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04787848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relistor Injectable Product
Description: Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relistor Injectable Product
Description: Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relistor Injectable Product
Description: Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relistor Injectable Product
Description: Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation
Study: NCT06339775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment.~(MNC infusion is about 5×10\^7/kg\~1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 （8 to 21 days in total）, followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg\~1×10\^8/kg).
Study: NCT05114473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Workshops
Description: Several face-to-face workshops given by a researcher

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online-accessed material
Description: Access to a website containing the educational program
Study: NCT06349811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M05D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT05658497

Intervention type: DRUG
Intervention: Diroximel Fumarate
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Intervention: Avonex
Description: Administered as specified in the treatment arm.

Intervention type: BIOLOGICAL
Intervention: Tysabri
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Intervention: Dimethyl Fumarate
Description: Administered as specified in the treatment arm.
Study: NCT05702814

Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered.

Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered.

Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered.

Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered.
Study: NCT06511453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure (using AcuWand or pencil eraser)
Description: The acupressure procedure will consist of medium-deep pressure as tolerated at each assigned point applied in a circular motion. Subjects will be trained in the appropriate performance of the treatment at all points and complete the first treatment under supervision. Acupressure treatment will last for 2-3 minutes per point and be administered remotely every other day for 5 weeks.~Acupressure will be performed using a tool (AcuWand) and a pencil (the pencil's eraser head will be used as an alternative/backup tool) will be provided to help participants apply the right amount of pressure on the appropriate points on their bodies. In the event AcuWand/pencil is not available, participants can use fingers/thumbs for self-acupressure.
Study: NCT06303505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUB-040
Description: A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUB-040
Description: A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle
Study: NCT04817761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calaspargase pegol (S95015)
Description: Part 1: S95015 will be administered at dose of 2000 U/m2, 1500 U/m2 or 1000 U/m2 (dose level based on age and BMI) via a 2-hour intravenous infusion at Day 4 (or 5, or 6) of the induction phase, Days 15 and 43 of the consolidation phase, Day 22 of the interim maintenance phase and Days 4 (or 5, or 6) and 43 of the delayed intensification phase. S95015 starting doses for age and BMI groups will be confirmed.~Patients will receive premedication prior to calaspargase pegol administration (acetaminophen, histamine-1 blocker, and corticosteroids to prevent hypersensitivity reaction) and other backbone chemotherapy agents based on the CALGB 10403 protocol treatment regimen.~Part 2: Patients aged 22 to 39 years + BMI ≤ 35 kg/m2 will be treated with S95015 1750 U/m2.~Patients aged 40 to \< 55 years + BMI ≤ 35 kg/m2 will be treated with S95015 1500 U/m2, unchanged from Part 1. Patients 55 years or older or those with a BMI greater than 35 kg/m2 will no longer be enrolled into Part 2.
Study: NCT06498011

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Graded Repetitive Arm Supplementary Program (GRASP)
Description: The home-based exercise programme will be based on the Home Graded Repetitive Arm Supplementary Program focusing on stretching, arm strengthening, hand strengthening, coordination and hand skills. The Home Graded Repetitive Arm Supplementary Program will be delivered 2 hours/session, 3 times/week, for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated Somatosensory-MOtor training using a COgnitive approach(iCOSMO)
Description: The first training approach of iCOSMO will focus on integrated somatosensory-motor variables during reaching and object manipulation (60 minutes). The second training approach will focus on proprioceptive, motor and cognitive tasks using the Kinarm robotic exoskeleton (60 minutes). iCOSMO will be delivered 3 times per week (2 hours per session) for 6 weeks (Total: 36 hours of treatment).
Study: NCT05638698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG01 Vaccine
Description: used to assess molecular disease control rate when combined with other interventional methods.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG01 Vaccine
Description: used to assess molecular disease control rate when combined with other interventional methods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QS-21
Description: used to assess molecular disease control rate when combined with other interventional methods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QS-21
Description: used to assess molecular disease control rate when combined with other interventional methods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: used to assess molecular disease control rate when combined with other interventional methods.
Study: NCT05153720

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Ultrasound guided erector spinae plane block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block
Description: Ultrasound guided caudal block
Study: NCT05118828

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided internet-based cognitive behavioural therapy
Description: AS-iCBT offers guided CBT intervention for anxiety and depression, each consisting of 6 modules. It is recommended for clients to complete 1 module weekly. The structure and content of the programme modules follow evidence-based CBT principles, and comprises cognitive and behavioural components such as self-monitoring, gradual stimulus control, exposure, behavioural activation, and cognitive restructuring. It is recommended that therapist support is provided weekly during short sessions that focus on progress monitoring and feedback on completed work. Support sessions should last 15-20 minutes and are preferably delivered by phone or video conference.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual in Prompt Mental Health Care (TAU-PMHC)
Description: TAU-PMHC includes both low-intensity (guided self-help, group-based psychoeducation) and high-intensity CBT (F2F-CBT). The TAU-PMHC condition basically represents how PMHC services currently operates (i.e. a pragmatic stepped care model) and provides therapists with more flexibility to accommodate client needs and preferences.
Study: NCT06374108

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive resistance training
Description: The RT exercise regime will focus on lower extremity exercises (60-90% of 1 repetition maximum) as well as incorporating functional exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive resistance training
Description: The RT exercise regime will focus on lower extremity exercises (60-90% of 1 repetition maximum) as well as incorporating functional exercises.
Study: NCT06350682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HealthMPowerment (HMP)
Description: Participants will be provided access to the status neutral platform (HMP)mobile app for 12 months exposure period or a delayed access period. The HMP is developed specific to RISE and will be adapted based off feedback from each local site via stakeholders/YABs. The HMP will encompass a range of features including a robust content management system and back end administrative dashboard, multi media resources and information center, social support features such as connections to peers and providers, interactive activities and self assessments, and flexible medication and health trackers. In addition the app will support HIV/STI test kit ordering and results portal and a gamified reward system. With real time analytics to monitor user engagement and response with the DHI we can adapt the delivery of tailored content to fit emergent HIV prevention and care challenges.
Study: NCT04914429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab 100 mg will be administered as a SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guselkumab
Description: Guselkumab 100 mg will be administered as a SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as a SC injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as a SC injection.
Study: NCT06084923

Intervention type: OTHER
Intervention: Observation
Description: Patients will be observed after ibrutinib discontinuation and data on ibrutinib discontinuation, reatreatment and outcome will be collected
Study: NCT05537116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback
Description: Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback. Feedback will include the following elements: a personalized substance use profile and substance-impaired driving profile, information on social norms related to substance use and substance-impaired driving, personalized information on BAC (or level of impairment due to drug use) prior to driving, costs associated with a DUI citation in Kentucky, and information on combined drug and alcohol impaired driving risk (if endorsed).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized feedback and text messages
Description: Following the baseline assessment, participants will be sent a link via text message to a secure website containing substance-impaired driving specific personalized feedback (described above). Participants will be asked to send a text message back to the study administrator after viewing the feedback document. After confirming receipt and processing of the document, the study administrator will then send the participant three text messages containing open-ended questions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Only
Description: Students randomized to the information condition will receive standard information about alcohol and other drugs and substance-impaired driving via a link to a website delivered through text message.
Study: NCT06643039

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nasopharyngeal swab
Description: Nasopharyngeal swab collection will be carried out in patients and health care professionals presenting an ILI during the study period. This will be done by trained clinical research associates after the signature of the consent. Only one nasopharyngeal sample is expected to be collected from each participant.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode.

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: questionnaire including demographic data, data on medical history and vaccination, and clinical and biological data on the viral episode.
Study: NCT05089656

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OAV101
Description: Gene therapy

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: The sham procedure will consist of a small needle prick on the lower back at the location where the LP injection is normally made. The needle will break the skin, but no needle insertion for lumbar puncture will occur.
Study: NCT04635475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE Bundle
Description: Toolkit to build capacity where students receive education and provide symptom based and tailored accommodations after concussion
Study: NCT06571760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertex Pulmonary Embolectomy System
Description: Use of Vertex Pulmonary Embolectomy System to treat pulmonary embolism.
Study: NCT06487845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: IR tablets, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3283142
Description: IR tablets, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to BAY3283142
Study: NCT05677997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Sessions to go through goals, problem areas, areas they want to improve.
Study: NCT06513065

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin c
Description: Mitomycin is a tumour antibiotic isolated from the broth of Streptomyces species. It has alkylating properties, which results in DNA cross-linking. Once MMC enters the tumour cell, it needs microsomal modification by various enzymes to be transformed into active state; free radicals constituted of semiquinones of MMC are responsible for its cytotoxic effects.~Mitomycin is licenced in the UK and recommended by NICE for intraperitoneal chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin c
Description: Mitomycin is a tumour antibiotic isolated from the broth of Streptomyces species. It has alkylating properties, which results in DNA cross-linking. Once MMC enters the tumour cell, it needs microsomal modification by various enzymes to be transformed into active state; free radicals constituted of semiquinones of MMC are responsible for its cytotoxic effects.~Mitomycin is licenced in the UK and recommended by NICE for intraperitoneal chemotherapy.
Study: NCT06605053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-produced intervention to optimize PMTCT care engagement
Description: While the specific interventions package will developed earlier in the project, it may include evidence-based approaches such as peer mentor mothers, male partner involvement, flexible hours for girls/young women and mobile phone reminders. Overall, the interventions should be brief and easy to integrate into standard care, aiming to 'nudge' or motivate participants (towards improved engagement, retention, and outcomes) as well as health care providers or community stakeholders to better understand and support girls/young women\&#39;s specific needs. A focal team of 2-3 persons will be trained and engaged to drive the implementation of the interventions at randomized faciltiies. The focal team will orient and engage other staff and stakeholders to deliver the interventions, identify and address gaps, and monitor implementation fidelity and quality using standard operating procedures.
Study: NCT06608147

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sampling
Description: sternal bone marrow aspiration
Study: NCT04950400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrelizumab + chemotherapy + apatinib
Description: Subjects will receive 200 mg of karizumab every three weeks，Pemetrexed 500 mg / m2 was given on the first day of each cycle,Every three weeks was a period of administration,Carboplatin AUC 5 was given on the first day of each cycle and every three weeks was a cycle，Paclitaxel 175 mg / m2 was given on the first day of each cycle, and every three weeks was an administration cycle，with intravenous drip，Apatinib, 250 mg, oral, once a day (PO, QD), every 3 weeks as a cycle.
Study: NCT06358729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Typical Nipple
Description: Infants are fed their typical milk/formula by their caregiver when hungry, one feeding with their typical nipple.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Typical Nipple
Description: Infants are fed their typical milk/formula by their caregiver when hungry, one feeding with their typical nipple.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenging Nipple
Description: Infants are fed with a smaller sized nipple (i.e. with a smaller aperture, slowing the rate of milk delivery).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenging Nipple
Description: Infants are fed with a smaller sized nipple (i.e. with a smaller aperture, slowing the rate of milk delivery).
Study: NCT05157269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Two NTZ 300 mg extended release tablets administered orally with food twice daily for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two matching placebo tablets administered orally twice daily for 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin Super-B Complex
Description: Vitamin Super-B Complex administered orally with food twice daily for 5 days to maintain the blind

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Super-B Complex
Description: Vitamin Super-B Complex administered orally with food twice daily for 5 days to maintain the blind
Study: NCT06674915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 capsules
Description: Oral 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 capsules
Description: Oral 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-5965 capsules
Description: Oral 50 mg.
Study: NCT06622655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powered orthosis
Description: Home rehabilitation (2 months, 30 minutes/day, 5 days/week) during which subjects will practice walking with the device at home.
Study: NCT06723340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scar gel
Description: Scar gel (medical device - topical application)
Study: NCT06728709

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound detection of any abnormal ultrasonographical findings.
Description: ultrasound assessment within 24 hours. Then reassessment every 48 hours or when the patient develops respiratory distress.~While the patient is in a supine or semi-recumbent position, and the probe is in a short axis. The 12-region technique will be used. The areas are six on each side of the chest. each region will be scored using the LUS aeration score. as follows: 0, A-pattern with 0-2 B-lines; 1, more than 2 separated B-lines; 2, multiple coalescent B-lines; or 3, lung consolidation, . A global LUS score will be calculated at each time point and range from 0 to 36.~If posterior regions couldn't be done. The examiner will assess 8 regions -Anterior chest wall ( ACW), Anterior axillary line (AAXL), costo-phrenic angle (COSTO), Postero-lateral alveolar \&/ or pleural syndrome (PLAPS) right and left -will be scored.~The venous status will be assessed through a subcostal view for inferior vena cava diameter.

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound detection of any abnormal ultrasonographical findings.
Description: ultrasound assessment within 24 hours. Then reassessment every 48 hours or when the patient develops respiratory distress.~While the patient is in a supine or semi-recumbent position, and the probe is in a short axis. The 12-region technique will be used. The areas are six on each side of the chest. each region will be scored using the LUS aeration score. as follows: 0, A-pattern with 0-2 B-lines; 1, more than 2 separated B-lines; 2, multiple coalescent B-lines; or 3, lung consolidation, . A global LUS score will be calculated at each time point and range from 0 to 36.~If posterior regions couldn't be done. The examiner will assess 8 regions -Anterior chest wall ( ACW), Anterior axillary line (AAXL), costo-phrenic angle (COSTO), Postero-lateral alveolar \&/ or pleural syndrome (PLAPS) right and left -will be scored.~The venous status will be assessed through a subcostal view for inferior vena cava diameter.
Study: NCT06727565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously